• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脂蛋白(a)与内在和氯吡格雷抵抗的血小板反应之间的关系。

Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity.

机构信息

Department of Cardiology and Angiology II, Medical Center, University of Freiburg, University Heart Center Freiburg-Bad Krozingen, Suedring 15, 79189, Bad Krozingen, Germany.

Cantonal Hospital Baselland, Liestal, Switzerland.

出版信息

J Thromb Thrombolysis. 2022 Jan;53(1):1-9. doi: 10.1007/s11239-021-02515-2. Epub 2021 Jul 2.

DOI:10.1007/s11239-021-02515-2
PMID:34213715
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8791920/
Abstract

Lipoprotein(a) [Lp(a)] is an independent, genetically determined, and causal risk factor for cardiovascular disease. Laboratory data have suggested an interaction of Lp(a) with platelet function, potentially caused by its interaction with platelet receptors. So far, the potential association of Lp(a) with platelet activation and reactivity has not been proven in larger clinical cohorts. This study analyzed intrinsic platelet reactivity before loading with clopidogrel 600 mg and on-treatment platelet reactivity tested 24 h following loading in patients undergoing elective coronary angiography. Platelet reactivity was tested by optical aggregometry following stimulation with collagen or adenosine diphosphate as well as by flow cytometry. Lp(a) levels were directly measured in all patients from fresh samples. The present analysis included 1912 patients. Lp(a) levels ranged between 0 and 332 mg/dl. There was a significant association of rising levels of Lp(a) with a higher prevalence of a history of ischemic heart disease (p < 0.001) and more extensive coronary artery disease (p = 0.001). Results for intrinsic (p = 0.80) and on-clopidogrel platelet reactivity (p = 0.81) did not differ between quartiles of Lp(a) levels. Flow cytometry analyses of expression of different platelet surface proteins (CD41, CD62P or PAC-1) confirmed these findings. Correlation analyses of levels of Lp(a) with any of the tested platelet activation markers did not show any correlation. The present data do not support the hypothesis of an interaction of Lp(a) with platelet reactivity.

摘要

脂蛋白(a)[Lp(a)]是心血管疾病的独立、遗传决定和因果风险因素。实验室数据表明,Lp(a)与血小板功能相互作用,这可能是由于其与血小板受体相互作用所致。迄今为止,尚未在更大的临床队列中证明 Lp(a)与血小板激活和反应性之间的潜在关联。本研究分析了在接受选择性冠状动脉造影的患者中,在服用氯吡格雷 600mg 前测定的血小板固有反应性和服用氯吡格雷 24 小时后的血小板反应性。通过光学聚集法在胶原或二磷酸腺苷刺激下以及通过流式细胞术测定血小板反应性。所有患者均从新鲜样本中直接测量 Lp(a)水平。本分析包括 1912 例患者。Lp(a)水平在 0 至 332mg/dl 之间。Lp(a)水平升高与缺血性心脏病史(p<0.001)和更广泛的冠状动脉疾病(p=0.001)的患病率升高呈显著相关。固有(p=0.80)和氯吡格雷后血小板反应性(p=0.81)的结果在 Lp(a)水平四分位数之间没有差异。不同血小板表面蛋白(CD41、CD62P 或 PAC-1)表达的流式细胞术分析证实了这些发现。Lp(a)水平与任何测试的血小板激活标志物之间的相关性分析未显示出任何相关性。本数据不支持 Lp(a)与血小板反应性相互作用的假设。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9381/8791920/fd065e73b441/11239_2021_2515_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9381/8791920/532c083d6456/11239_2021_2515_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9381/8791920/6945e3c23909/11239_2021_2515_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9381/8791920/48ec085a72be/11239_2021_2515_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9381/8791920/fd065e73b441/11239_2021_2515_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9381/8791920/532c083d6456/11239_2021_2515_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9381/8791920/6945e3c23909/11239_2021_2515_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9381/8791920/48ec085a72be/11239_2021_2515_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9381/8791920/fd065e73b441/11239_2021_2515_Fig4_HTML.jpg

相似文献

1
Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity.脂蛋白(a)与内在和氯吡格雷抵抗的血小板反应之间的关系。
J Thromb Thrombolysis. 2022 Jan;53(1):1-9. doi: 10.1007/s11239-021-02515-2. Epub 2021 Jul 2.
2
Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.接受氯吡格雷或替格瑞洛双重抗血小板治疗的患者的维生素D水平与高残余血小板反应性
Platelets. 2016 Sep;27(6):576-82. doi: 10.3109/09537104.2016.1149159. Epub 2016 Apr 11.
3
Elevated High-Sensitivity C-Reactive Protein Level Enhances the Impact of Lipoprotein(a) on Platelet Reactivity in PCI Patients Treated with Clopidogrel.载脂蛋白(a)水平升高对氯吡格雷治疗的经皮冠状动脉介入治疗患者血小板反应性的影响增强。
Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241280711. doi: 10.1177/10760296241280711.
4
Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor.接受氯吡格雷或替格瑞洛治疗的患者中的尿酸与高残余血小板反应性
Nutr Metab Cardiovasc Dis. 2016 Apr;26(4):352-8. doi: 10.1016/j.numecd.2015.12.015. Epub 2016 Jan 6.
5
Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.替格瑞洛或氯吡格雷双联抗血小板治疗期间的血清尿酸水平:一项单中心研究的结果
Nutr Metab Cardiovasc Dis. 2016 Jul;26(7):567-574. doi: 10.1016/j.numecd.2016.03.001. Epub 2016 Mar 15.
6
Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.使用氯吡格雷或替格瑞洛进行双重抗血小板治疗期间的体重指数与血小板反应性
J Cardiovasc Pharmacol. 2015 Oct;66(4):364-70. doi: 10.1097/FJC.0000000000000288.
7
Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.接受阿司匹林与氯吡格雷或替格瑞洛双联抗血小板治疗患者的甲状旁腺激素水平与高残余血小板反应性
Cardiovasc Ther. 2016 Aug;34(4):209-15. doi: 10.1111/1755-5922.12188.
8
Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.服用氯吡格雷或替格瑞洛双联抗血小板治疗的患者的平均血小板体积和高残余血小板反应性。
Expert Opin Pharmacother. 2015;16(12):1739-47. doi: 10.1517/14656566.2015.1056151. Epub 2015 Jun 12.
9
Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor.接受氯吡格雷或替格瑞洛双重抗血小板治疗的肾功能受损患者的血小板反应性
Vascul Pharmacol. 2016 Apr;79:11-15. doi: 10.1016/j.vph.2015.10.006. Epub 2015 Oct 28.
10
Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy.接受双联抗血小板治疗患者血小板反应性的性别差异
Cardiovasc Drugs Ther. 2016 Apr;30(2):143-50. doi: 10.1007/s10557-016-6646-5.

引用本文的文献

1
Oxidized Phospholipids on Apo B, Platelet Activation and Reactivity, and Long-Term Cardiovascular Outcomes.载脂蛋白B上的氧化磷脂、血小板活化与反应性以及长期心血管结局
Arterioscler Thromb Vasc Biol. 2025 Aug 14. doi: 10.1161/ATVBAHA.125.322347.
2
Lipoprotein(a), platelet function and cardiovascular disease.脂蛋白(a)、血小板功能与心血管疾病。
Nat Rev Cardiol. 2024 May;21(5):299-311. doi: 10.1038/s41569-023-00947-2. Epub 2023 Nov 8.

本文引用的文献

1
Relation of High Lipoprotein (a) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease.载脂蛋白(a)浓度与冠心病及非冠心病患者血小板反应性的关系。
Adv Ther. 2020 Nov;37(11):4568-4584. doi: 10.1007/s12325-020-01483-y. Epub 2020 Sep 5.
2
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.依洛尤单抗对急性冠状动脉综合征后脂蛋白(a)和心血管风险的影响。
J Am Coll Cardiol. 2020 Jan 21;75(2):133-144. doi: 10.1016/j.jacc.2019.10.057.
3
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.
脂蛋白(a)降低与心血管疾病患者。
N Engl J Med. 2020 Jan 16;382(3):244-255. doi: 10.1056/NEJMoa1905239. Epub 2020 Jan 1.
4
Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis.在人体中,用反义寡核苷酸强力降低血浆脂蛋白(a)不会影响体外纤溶。
J Lipid Res. 2019 Dec;60(12):2082-2089. doi: 10.1194/jlr.P094763. Epub 2019 Sep 24.
5
Statin therapy increases lipoprotein(a) levels.他汀类药物治疗会升高脂蛋白(a)水平。
Eur Heart J. 2020 Jun 21;41(24):2275-2284. doi: 10.1093/eurheartj/ehz310.
6
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.脂蛋白(a)、前蛋白转化酶枯草溶菌素 9 抑制剂与心血管风险。
Circulation. 2019 Mar 19;139(12):1483-1492. doi: 10.1161/CIRCULATIONAHA.118.037184.
7
Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis.载脂蛋白 LPA 变异与冠心病风险的关联及对脂蛋白(a)降低治疗的意义:一项孟德尔随机分析。
JAMA Cardiol. 2018 Jul 1;3(7):619-627. doi: 10.1001/jamacardio.2018.1470.
8
Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.脂蛋白(a)作为心血管疾病的一个病因:来自流行病学、遗传学和生物学的见解
J Lipid Res. 2016 Nov;57(11):1953-1975. doi: 10.1194/jlr.R071233. Epub 2016 Sep 27.
9
Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States.美国532359例患者中脂蛋白(a)质量水平升高的患病率及患者阈值
Arterioscler Thromb Vasc Biol. 2016 Nov;36(11):2239-2245. doi: 10.1161/ATVBAHA.116.308011. Epub 2016 Sep 22.
10
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.靶向载脂蛋白(a)的反义治疗:一项随机、双盲、安慰剂对照的 1 期研究。
Lancet. 2015 Oct 10;386(10002):1472-83. doi: 10.1016/S0140-6736(15)61252-1. Epub 2015 Jul 22.